Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Completed · Phase 4

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to explore whether DMF (Dimethyl Fumarate) or MMF (monomethyl fumarate) its main bioactive metabolite, is capable of entering the central nervous system in SPMS patients that are being treated with Tecfidera®. PK samples (pharmacokinetics - or the amount of study drug in blood) will be tested to compare with PK samples, the amount of study drug, in spinal fluid (CSF).

Key facts

Study ID

NCT02683863

Run by

Multiple Sclerosis Center of Northeastern New York

People needed

20

Starts

2015-08-01

Expected to finish

2017-01-31

Last updated by the study team

2017-03-22

Who can join

Age: 25 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

• Multiple Sclerosis Center of Northeastern New York — Latham, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.